GLP-1 Injection Guide · Last verified: May 9, 2026

GLP-1 Injection Site Rotation Guide: A Verified 12-Week Map

By WPG Research Team · Last verified: May 9, 2026 — against FDA prescribing information for Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Bydureon BCise, Byetta, and Adlyxin, plus the FITTER Forward 2025 expert recommendations published in Mayo Clinic Proceedings.

Next re-verification: August 2026

The Short Answer

Inject under the skin of your abdomen, front of the thigh, or back of the upper arm. Move to a different exact spot every week. Stay about 1 cm — roughly one adult finger-width — from your last injection. For belly injections, keep at least 2 inches away from your belly button.

Same area is okay. Same exact spot is the problem. Always inspect.

What this guide is, and isn't. This is a rotation guide for adults already prescribed an injectable GLP-1 or GIP/GLP-1 medication. It does not tell you whether to start, stop, change, split, or repeat a dose. It does not replace the Instructions for Use that came with your medication. For anything beyond rotation — device confusion, missed dose, side effects, or symptoms — the right answer is your prescribing clinician or pharmacist.

Pick Your Next Injection Site

If this is your situation today	Do this	Then check before you inject
First weekly dose ever	Use the abdomen, at least 2 inches from your belly button. It's the easiest place to see and gives you the most rotation room.	Skin should be clean, dry, smooth — no bruise, lump, or rash.
You injected last week and forgot exactly where	Switch sides. If last week was right, use left today, at least a finger-width from any spot you can identify as recent.	Skim the area with your fingertips. If anything feels firm, raised, or tender, move at least 2 inches away.
You want to stay on your stomach	You can — same body area is allowed by every major GLP-1 label. Just pick a different exact spot.	Avoid the 2-inch ring around your belly button and your waistband line.
Your abdomen is sore or running out of fresh skin	Move to the front of the thigh, in the area shown in your Instructions for Use.	Don't improvise on the inner thigh just because it looks reachable.
You want to use the upper arm	You'll need help. Mounjaro, Zepbound, and Trulicity instructions all say another person should inject the back of the upper arm.	Helper aims for the outer fleshy part, between shoulder and elbow.
You see a small bruise or bump from last week	Skip that spot. Go to a clean zone at least 2 inches away.	If the spot is firm and rubbery 2+ weeks later, mention it to your prescriber.
You use compounded semaglutide or tirzepatide from a vial	Same three body areas. Follow the dosing and needle instructions from your prescribing pharmacy.	Compounded products do not have one FDA-approved label — your prescription instructions are the source of truth.

Stated vs. verified: Label rule: rotate the exact site with each dose. FITTER spacing recommendation: about 1 cm from the last injection. Our map default for the abdomen: a 2-inch belly-button buffer and 12 weekly zones. The first two come from official sources. The third is our editorial framework built on top of them.

Where Can You Inject a GLP-1 Medication?

For the injectable GLP-1 and GIP/GLP-1 products covered in this guide, the U.S. FDA-approved labels list three injection sites: the abdomen (stomach), the front of the thigh, and the back of the upper arm. Subcutaneous (under the skin, not into muscle or vein) is the only correct route.

The Abdomen

The default site — easy to see, easy to reach, and gives most self-injectors a large rotation surface. Stay at least 2 inches away from your belly button in any direction. Avoid your waistband area, visible C-section or surgical scars, and the dense center of any large stretch-mark cluster. Stretch marks themselves aren't a problem.

Tip: Lay two adult fingers side by side starting at your navel — inject anywhere outside that ring.

Front of the Thigh

Best for patients who like to inject seated. Use the middle third of the front or outer-front of the thigh, roughly halfway between hip and knee. The thigh has a smaller usable surface than the abdomen — if you rotate only between thighs, you'll cycle through spots faster.

Tip: Don't improvise outside the area shown in your product's Instructions for Use.

Back of the Upper Arm

Approved by the FDA for every major injectable GLP-1, but with a real-world catch most pages skip: the manufacturer instructions for Mounjaro, Zepbound, and Trulicity all say another person should inject the back of the upper arm. If you inject alone, plan around the abdomen and thigh.

Tip: Target the outer fleshy part between shoulder and elbow — not the inner arm.

Where You Should Never Inject

Into muscle — if the needle goes too deep, pinch a fold of skin first

Into a vein — these medications are labeled for subcutaneous injection only

The same exact spot two weeks in a row

Skin that is bruised, red, hard, lumpy, tender, scarred, or actively irritated

Through clothing

The buttocks — not listed in U.S. labels for any product in this guide

How Often Should You Rotate GLP-1 Injection Sites?

Every weekly GLP-1 medication's FDA-approved prescribing information instructs patients to rotate the injection site with each dose. You should not use the same exact spot two weeks in a row. The FITTER Forward 2025 expert recommendations add a specific spacing rule: keep injections about 1 cm — roughly a finger-width — apart from previous sites, and rotate systematically. For daily medications like Saxenda and Victoza, the labels explicitly warn that repeated injections in the same spot can cause cutaneous amyloidosis.

What Each Label Actually Says

Wegovy:"Change (rotate) your injection site with each injection. Do not use the same site for each injection."

Ozempic:Use a different injection site each week when injecting in the same body region.

Mounjaro & Zepbound:"Rotate injection sites with each dose."

Trulicity:Rotate injection sites with each dose; same body area is fine if you use a different spot.

Saxenda & Victoza (liraglutide):"Rotate injection sites within the same region in order to reduce the risk of cutaneous amyloidosis."

Notice none of those instructions tell you how to rotate — only that you must. The "how" is what the 12-week map below is for.

Should You Switch Body Parts Every Week, or Stay in the Same Area?

Manufacturer prescribing information requires only that you change the exact spot with each dose. Several labels explicitly allow staying in the same body area as long as the exact site changes. Any consistent, mapped pattern beats a random "switch body parts" approach.

Same area is okay. Same exact spot is the problem.

When Between-Region Rotation Actually Makes Sense

1Your favorite zone is sore, bruised, or recovering — don't power through it.

2You've lost significant abdominal fat — as body composition changes, the abdomen gives you less subcutaneous tissue. Move to thigh dominance.

3You have abdominal scars from surgery (C-section, tummy tuck, hernia repair) that limit your usable abdomen.

Which Rotation Pattern Is Right for Me?

3 quick questions → your recommended pattern (A, B, or C)

Question 1 of 3

How much abdominal fat do you have available for injections?

The 12-Week GLP-1 Rotation Map

This 12-week rotation map divides the abdomen into 8 quadrant zones (excluding the 2-inch radius around the navel) and assigns one zone per week. Consecutive weeks alternate sides of the body, and the second cycle of each zone is offset by at least a finger-width from the first. The map is our editorial construction — manufacturer labels require rotation but do not specify a 12-week schedule, and FITTER supports systematic rotation without prescribing this exact pattern.

Pattern A

Abdomen Only — Recommended Default

Picture your abdomen as a clock face with the belly button in the center. Divide it into four quadrants (upper-right, upper-left, lower-right, lower-left), then split each into outer and inner, giving you 8 distinct zones. Each zone gets a minimum of 8 weeks of recovery between visits.

Week	Zone	Side
Week 1	Lower outer	Right
Week 2	Upper outer	Right
Week 3	Upper inner	Right
Week 4	Lower inner	Right
Week 5	Lower outer	Left
Week 6	Upper outer	Left
Week 7	Upper inner	Left
Week 8	Lower inner	Left
Week 9	Lower outer, finger-width from week 1 spot	Right
Week 10	Upper outer, finger-width from week 2 spot	Right
Week 11	Upper inner, finger-width from week 3 spot	Right
Week 12	Lower inner, finger-width from week 4 spot	Right

Pattern B

Abdomen + Thigh — For Limited Abdominal Fat

If you've lost a meaningful amount of weight and your abdomen has less subcutaneous fat to work with, expand your map to include both thighs. Every spot gets at least 6 weeks of recovery while keeping most injections in the abdomen.

Week	Site	Zone
Week 1	Abdomen	Lower outer right
Week 2	Abdomen	Upper outer right
Week 3	Right thigh	Mid-front
Week 4	Abdomen	Upper inner right
Week 5	Abdomen	Lower inner right
Week 6	Left thigh	Mid-front
Week 7	Abdomen	Lower outer left
Week 8	Abdomen	Upper outer left
Week 9	Right thigh	Mid-front, finger-width from week 3
Week 10	Abdomen	Upper inner left
Week 11	Abdomen	Lower inner left
Week 12	Left thigh	Mid-front, finger-width from week 6

Pattern C

All Three Sites — With Caregiver Assistance for the Arm

Best when you have a reliable helper for the upper arm and want maximum rotation surface.

Week	Site	Zone	Self or helper
Week 1	Abdomen	Lower outer right	Self
Week 2	Abdomen	Upper outer left	Self
Week 3	Right thigh	Mid-front	Self
Week 4	Right upper arm	Outer back	Helper
Week 5	Abdomen	Lower outer left	Self
Week 6	Abdomen	Upper outer right	Self
Week 7	Left thigh	Mid-front	Self
Week 8	Left upper arm	Outer back	Helper
Week 9	Abdomen	Lower inner right	Self
Week 10	Abdomen	Upper inner left	Self
Week 11	Right thigh	Mid-front, finger-width from week 3	Self
Week 12	Right upper arm	Outer back, finger-width from week 4	Helper

Tracking tip: When you take your weekly dose, write the date and zone on a single line in your phone's notes app. Two seconds of work prevents a month of guessing. The trap to avoid is "I'll remember" — you won't, especially after week 4 when every previous spot looks identical.

Does the Injection Site Affect How Well Your GLP-1 Works?

For semaglutide and tirzepatide, the approved injection areas are not treated as dose-changing choices in the official data. Published pharmacokinetic analysis of subcutaneous semaglutide reports about 12% lower bioavailability in the thigh compared to the abdomen — but the authors and the FDA-approved label both describe the difference as not clinically relevant. Tirzepatide labeling describes similar exposure across all three sites. The much larger threat to medication effectiveness is injecting into damaged or lipohypertrophic tissue.

Semaglutide (Wegovy, Ozempic)

About 12% lower bioavailability in the thigh vs. abdomen. Authors and FDA label: not clinically relevant. No dose adjustment needed.

No practical difference

Tirzepatide (Mounjaro, Zepbound)

FDA label states absorption is "comparable" across abdomen, thigh, and upper arm. No site preference recommended.

Comparable across all sites

Liraglutide (Saxenda, Victoza)

Label explicitly states no dosage adjustment is needed if you change the injection site or timing.

No adjustment needed

What does matter: Whether you're injecting into healthy tissue. A spot that's developed lipohypertrophy or persistent nodules absorbs medication unpredictably — weeks where the medication "feels different," your appetite isn't suppressed as well, or your blood sugar fluctuates more than usual. The fix is rotation. Healthy tissue. Patient inspection.

Sources: Population PK analysis of semaglutide, Diabetes Therapy (Springer, 2019); Mounjaro prescribing information, FDA label revision 2024; Saxenda and Victoza labels, verified May 9, 2026.

What Does Each GLP-1 Medication's Label Actually Say?

Every U.S.-approved injectable GLP-1 medication lists abdomen, thigh, and upper arm as approved injection sites, and every label requires rotation. Three drugs — Mounjaro, Zepbound, and Trulicity — have an explicit instruction that another person should inject the back of the upper arm. Saxenda and Victoza carry an explicit cutaneous amyloidosis warning. Last verified May 9, 2026.

Medication	Drug	Frequency	Rotation language	Upper-arm caveat	U.S. status
Wegovy (injection)	Semaglutide	Weekly	"Change (rotate) your injection site with each injection. Do not use the same site for each injection."	Pen instructions: make sure dose window is visible during injection.	Available
Ozempic (injection)	Semaglutide	Weekly	"Use a different injection site each week when injecting in the same body region."	None specified.	Available
Mounjaro	Tirzepatide	Weekly	"Rotate injection sites with each dose."	"Another person should inject in the back of the upper arm."	Available (pen, KwikPen, vial)
Zepbound	Tirzepatide	Weekly	"Rotate injection sites with each dose."	"Another person should inject in the back of the upper arm."	Available (pen, KwikPen, vial)
Trulicity	Dulaglutide	Weekly	Rotate with each dose; same area is fine if you use a different spot.	Manufacturer instructions: another person should give the injection in the back of the upper arm.	Available
Saxenda	Liraglutide	Daily	"Rotate injection sites within the same region in order to reduce the risk of cutaneous amyloidosis."	None specified.	Available
Victoza	Liraglutide	Daily	"Rotate injection sites within the same region to reduce the risk of cutaneous amyloidosis."	None specified.	Available; generic also marketed
Bydureon BCise	Exenatide ER	Weekly	Use a different injection site each week when injecting in the same region.	None specified.	Discontinued Oct 28, 2024
Byetta	Exenatide	Twice daily	Rotate injection sites with each dose; do not use the same site.	None specified.	Discontinued Oct 25, 2024; generic FDA-approved Nov 2024
Adlyxin	Lixisenatide	Daily	Rotate within the area chosen; do not use the same spot for each injection.	None specified.	Verify availability with your pharmacy

For daily medications (Saxenda, Victoza, Adlyxin): Rotation matters more than for weekly drugs because you're injecting 7 times per week instead of once. You'll cycle through your usable spots faster and the cumulative tissue stress per area is higher. The cutaneous amyloidosis warning on liraglutide labels is the most specific lump-related warning on any GLP-1 label.

Note: Oral semaglutide products (Rybelsus, Ozempic tablets, Wegovy tablets) are excluded — taken by mouth, no injection site. International labels may have different language — we checked U.S. FDA-approved versions only.

If you're comparing GLP-1 providers and want to know which platform gives you the best medication access, device support, and clinician availability, see our full provider comparison or take our 60-second matching quiz.

What Device Do You Actually Have?

The injection-site map on this page applies to every injectable GLP-1, but the injection technique itself depends entirely on your specific device. Do not borrow injection steps from one device's Instructions for Use to use with another. A vial does not automatically mean compounded — branded vials and compounded vials are different things.

What you have	Where injection steps come from	Key caveat
Wegovy single-dose pen	Wegovy Instructions for Use included with the pen	Pen has a yellow indicator bar; hold against skin until the bar stops moving
Ozempic multi-dose pen	Ozempic Instructions for Use plus separately attached NovoFine pen needle	Needle is supplied separately; attach a fresh needle each dose
Mounjaro single-dose pen	Mounjaro pen Instructions for Use	Pen auto-injects when pressed against skin
Mounjaro KwikPen	Mounjaro KwikPen Instructions for Use (different from single-dose pen)	Multiple doses per pen; dial the dose, do not guess
Mounjaro single-dose or multi-dose vial	Mounjaro vial Instructions for Use	FDA-labeled product; you draw from the vial with a syringe
Zepbound single-dose pen	Zepbound pen Instructions for Use	Press and hold; visual indicator confirms full dose
Zepbound KwikPen	Zepbound KwikPen Instructions for Use	Different steps from the single-dose pen
Zepbound single-dose vial	Zepbound vial Instructions for Use	FDA-labeled product; draw with a syringe
Trulicity autoinjector	Trulicity Instructions for Use	Auto-fires when pressed against skin
Saxenda or Victoza multi-dose pen	Liraglutide pen Instructions for Use	Daily dosing; dial the dose for each injection
Compounded semaglutide or tirzepatide vial	Your prescribing pharmacy's exact instructions	No FDA-approved label; the pharmacy's instructions are the source of truth

Lipohypertrophy, Nodules, and What to Actually Watch For

Lipohypertrophy is a firm, rubbery thickening of fatty tissue caused by repeated injections in the same spot. Injection-site nodules — small firm bumps under the skin — are a recognized reaction to several GLP-1 drugs. The Saxenda and Victoza labels specifically warn about cutaneous amyloidosis and recommend rotation within the same region. Rotation is the primary prevention. If you can feel firm tissue at a former injection site, stop using that spot.

Injection-site nodules

Documented in a published case series with semaglutide use. The exenatide extended-release product (Bydureon, before discontinuation) had a particularly high rate — about 17% of clinical trial users reported small, asymptomatic injection-site nodules.

General injection-site reactions

Redness, itching, swelling, mild pain — listed across GLP-1 labels at varying rates. Specific rates depend on the drug and device.

Cutaneous amyloidosis

Specifically called out on the Saxenda and Victoza (liraglutide) labels as a risk that rotation reduces. Buildup of protein deposits under the skin caused by repeated injections in the same area. Can cause firm lumps that may not fully resolve.

How to Detect It — The Fingertip Check

Run your fingers in slow circles over a former injection site. Healthy tissue feels smooth and soft. Damaged tissue feels firmer, raised, sometimes rubbery, sometimes denser. It might be slightly numb to touch — which is part of why patients sometimes prefer injecting there. A 2-inch firm patch under your skin that's been there 2+ weeks is your signal to stop using that area entirely.

How Long Damaged Tissue Takes to Recover

Type	Typical recovery time
Mild irritation and ordinary bumps	24–72 hours
Bruises	5–10 days
Injection-site nodules	4–12 weeks typical softening
True lipohypertrophy	Many months; some persistent changes may not fully reverse

What to Do If You Notice a Lump, Bruise, or Sore Spot

A small bruise, mild redness, or a small bump that fades within 24–72 hours after injection is usually a rotation problem, not a panic problem. Run through this 30-second check before every injection.

IF: Smooth skin, no firmness, no redness, no tenderness?

→ Inject as planned.

IF: Small bruise (purple or yellow) but no firmness, no pain?

→ Pick a different zone today. The bruised zone is fine to use again next cycle.

IF: Small pink bump or mild redness that fades when you press it?

→ Pick a different zone today. Recheck next week.

IF: Firm, rubbery, raised, ≥1 inch across, persists 2+ weeks?

→ Stop using that zone. Rotate to a fresh zone. Mention it at your next prescriber visit.

IF: Expanding redness, warmth, pus, fever, or pain that worsens over 24 hours?

→ Call your provider today. This could be infection.

IF: Hives, facial or tongue swelling, difficulty breathing?

→ Emergency. Call 911 or go to the ER.

The Most Common Worries, Answered

"There's a small drop of blood at the injection site."

Common. Press lightly with gauze or a cotton ball for a few seconds if your product instructions allow. Do not rub.

"There's a small clear or pink bead after I pulled the pen away."

A tiny drop can happen. Do not re-inject unless your device instructions, pharmacist, or prescriber tell you to. Check your device's dose indicator to confirm the dose completed. If unsure, call before guessing.

"I have a bruise. Did I do something wrong?"

Probably not. Bruising happens when the needle nicks a small blood vessel. If you take blood thinners, aspirin, or NSAIDs regularly, expect more bruising — not your fault.

"I think I injected too close to my belly button."

Don't re-dose. Use the 2-inch buffer next time. If you're worried the dose didn't go in, check your device instructions or call your pharmacist.

"I used the same spot two weeks in a row by accident."

Once is fine. The rotation rule exists to prevent repeated use over weeks and months. Switch zones next week and start logging.

"I can feel a firm spot under my skin where I've been injecting."

Stop using that zone. Rotate to fresh tissue. The firm spot will soften over weeks. Mention it to your prescriber at your next visit so they can take a look.

How to Give Yourself the Injection

This guide is about where to inject, not how. Every GLP-1 device has its own step-by-step instructions, and they're not interchangeable. Use the Instructions for Use that came with your exact product. The general sequence below is a quick reference only — always defer to your device instructions for hold time, dose confirmation, and needle angle.

If your product instructions allow room-temperature use before injection, let it sit out exactly as instructed. Do not warm the medication with heat, hot water, a microwave, or your hands.

Wash your hands with soap and water.

Pick the site (using your rotation map) and clean it with an alcohol swab. Let it air-dry — wet alcohol stings on injection.

Pinch a fold of skin if your device instructions call for it. Insert the needle at the angle your device specifies (typically 90 degrees for pens). Press the device firmly until your specific device's indicator confirms the full dose.

Hold the device in place for the full duration and visual indicator your exact Instructions for Use requires. Do not copy Wegovy steps onto Mounjaro, Zepbound, or any other device.

Dispose of the needle or pen in a sharps container. Never recap. Never throw a used needle in regular trash.

Sharps disposal: The FDA recommends placing every used needle or sharps device into a designated sharps disposal container immediately after use. Keep away from children and pets. When the container is three-quarters full, dispose of it according to your state's rules. The FDA's "Safely Using Sharps at Home, at Work, and on Travel" page links to a state-by-state lookup.

How Is This Different If You Use Compounded Semaglutide or Tirzepatide?

Compounded GLP-1 medications do not have one FDA-approved label you can check. Your prescribing pharmacy's instructions are the source of truth. The FDA has received reports of adverse events, including some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide — specifically patients measuring incorrect doses and confusion between milligrams, milliliters, and units.

Same as branded products

The general anatomical regions (abdomen, thigh, upper arm)
The principle of rotating exact spots and avoiding damaged skin
The 12-week rotation logic you can build for yourself

Different from branded products

Device — most come in a multi-dose vial; you draw with a syringe
No FDA-approved label; your prescription instructions govern technique and storage
Dose measurement — you read off syringe markings; don't confuse mg, mL, and units
Multi-dose vials have a specific in-use expiration that varies by pharmacy

Branded Vial vs. Compounded Vial — Not the Same Thing

Feature	Branded vial (Mounjaro / Zepbound)	Compounded vial
FDA-approved labeling	Yes	No
Manufacturer Instructions for Use	Yes	No — your pharmacy's instructions only
Dose typically expressed as	A specific mg dose	Varies; may be mg, mL, or units
Syringe and needle	Manufacturer specifies in the IFU	Pharmacy specifies; do not guess from the internet
Concentration	Standardized	Varies by pharmacy

Questions to Ask Your Compounding Pharmacy Before Your First Injection

Which body areas should I use?

Which syringe and needle should I use?

What exact volume do I draw up, and is it expressed in mg, mL, or units?

How long is this vial good for after I open it?

What should I do if the medication looks cloudy or has particles?

What sharps container should I use?

FDA warning: Do not purchase unapproved GLP-1 products marketed as "for research use only" or "not for human consumption." These are of unknown quality, may not contain what they claim, and can be harmful. Buying compounded GLP-1s outside of a licensed prescribing relationship is a different category of risk than receiving them from a licensed 503A or 503B pharmacy with a valid prescription.

What If You Also Use Insulin or Another Injectable Medication?

If you use insulin and a GLP-1 in the same body region, give the injections separately — not in the same syringe, and not directly adjacent to each other. Per the FDA-approved labels for Ozempic, Mounjaro, and several other GLP-1s, the medications can share a body region but should not be injected next to each other.

Practical translation: if you inject your insulin in your abdomen, don't put your weekly GLP-1 right next to today's insulin spot. Use a different abdominal zone, use your thigh that week, or coordinate a rotation pattern with your provider so the two cycles never collide.

Edge Cases and Special Situations

"I've lost a lot of weight — my abdomen has less fat now"

Switch to Pattern B in the rotation map (abdomen + thigh). Use a shorter pen needle if your medication uses a separately attached needle (Ozempic, compounded) — 4mm pen needles work well even for very lean adults per the 2025 FITTER expert recommendations. Use the pinched skinfold technique to keep the needle in the subcutaneous layer instead of muscle.

"I'm very lean / athletic"

Shorter needle, pinched fold, and you may want to use thigh more than abdomen if your abdomen has minimal subcutaneous fat to work with.

"I have abdominal scars from surgery (C-section, hernia repair, tummy tuck)"

Stay at least an inch away from any visible scar tissue. Stretch marks themselves are fine to inject through. Major surgical scars are denser and have different absorption patterns — avoid them. Consider switching to Pattern B or C to expand your rotation surface.

"I missed a dose — does that change my rotation?"

No. Rotation is independent of dose timing. Pick up the next zone in your schedule whenever you take the next dose. Missed-dose timing rules differ by product — Mounjaro and Zepbound use a 4-day (96-hour) window; Wegovy injection uses a different rule. Check your own label or call your pharmacist before moving or replacing a dose.

"I switched medications — do I keep my old rotation log?"

Yes. The rotation logic is about your tissue, not the medication. If you were rotating through the same 8 abdomen zones on Wegovy and you switch to Mounjaro, keep the same map and just relabel. Your skin doesn't care which GLP-1 is in the syringe.

"I'm pregnant or breastfeeding"

This is a separate conversation with your prescriber. Most GLP-1 medications are not recommended during pregnancy. This page does not cover starting, stopping, or continuing GLP-1 medications during pregnancy.

Frequently Asked Questions

There is no single best site for every patient. The abdomen is the default for most self-injectors because it is easy to see, easy to reach, and gives the largest rotation surface. The front of the thigh and the back of the upper arm are equally valid. Pharmacokinetic data show no clinically meaningful difference in medication absorption between the three approved sites for semaglutide, tirzepatide, or liraglutide.

No. Every FDA-approved injectable GLP-1 label instructs patients to rotate the injection site with each dose. Repeated use of the same exact spot can cause lipohypertrophy, injection-site nodules, persistent bruising, and unpredictable medication absorption. The Saxenda and Victoza labels specifically warn about cutaneous amyloidosis, a type of skin lump caused by repeated injections in the same area.

Yes, as long as you use a different exact spot within that area. Wegovy, Ozempic, Mounjaro, Zepbound, and Trulicity instructions all explicitly allow same-area rotation as long as the exact spot changes. The 2025 FITTER expert guidance recommends keeping consecutive injections about 1 cm apart and rotating systematically.

At least 2 inches in any direction. Two adult fingers laid side-by-side starting at the navel marks the minimum safe distance. The Wegovy patient pen instructions specify this 2-inch rule explicitly. Other product instructions describe avoiding the area around the navel without always giving an exact distance, so the 2-inch rule is the clean default we use here.

No conclusive evidence supports this claim. Published pharmacokinetic data on semaglutide reports about 12% lower bioavailability in the thigh versus the abdomen, but the FDA, the manufacturer, and the published authors all describe this as not clinically relevant. Tirzepatide absorption is described as comparable across all three sites.

The FDA-approved patient instructions for Mounjaro, Zepbound, and Trulicity all specify that another person should inject the back of the upper arm. You can inject yourself in the abdomen or thigh; the upper arm is the site that, per the manufacturer, requires help.

Switch to the opposite side or a different body region today. Start logging immediately — your phone's notes app, a calendar, a sticky note, anything. Don't try to reconstruct the past four weeks from memory; just start fresh from today's dose.

No. Rubbing or massaging the injection site is not recommended; it can affect absorption and irritate the skin. Light pressure with gauze or a cotton ball for a few seconds is fine if you see a drop of blood.

Yes. The FDA recommends placing every used needle or sharps device into a sharps disposal container immediately after use. This prevents needlesticks, cuts, and punctures. Sharps containers are inexpensive and available at most pharmacies and online retailers.

No. Rybelsus, Ozempic tablets, and Wegovy tablets are oral semaglutide products. They're taken by mouth, not injected, so there's no injection site to rotate. This guide is for the injectable forms of GLP-1 and GIP/GLP-1 medications only.

Buttocks are not listed as an injection site in the U.S. labels we checked for the injectable GLP-1/GIP-GLP-1 products in this guide. Stick to abdomen, thigh, or upper arm/back of upper arm unless your prescriber gives you product-specific instructions.

A small bruise, mild redness, or a small bump that fades quickly is usually a rotation problem, not a panic problem. Skip that exact spot next time. If it's worsening, painful, spreading, draining, paired with fever, or doesn't go away, call your prescriber.

For injections, no. The FDA-approved labels for Wegovy injection, Ozempic injection, Mounjaro, and Zepbound all allow administration at any time of day, with or without meals. What matters is consistency — pick a day each week and stick to it.

How We Built This Guide and What We Verified

Last verified: May 9, 2026.

FDA prescribing information for Wegovy, Ozempic, Mounjaro, Zepbound, Trulicity, Saxenda, Victoza, Bydureon BCise, Byetta, and Adlyxin — pulled directly from accessdata.fda.gov and DailyMed.

Clinical guidance from the 2025 FITTER Forward expert recommendations published in Mayo Clinic Proceedings (Klonoff et al., April 2025). Disclosure: the FITTER Forward advisory board was funded by embecta, a manufacturer of injection devices. The paper states that authors retained final control of the manuscript content.

Pharmacokinetic data from the population PK analysis of subcutaneous semaglutide published in Diabetes Therapy (Springer, 2019) and the systematic review published in Clinical Pharmacokinetics (PMC, 2024).

Lipohypertrophy research including the 2024 systematic meta-analysis (PMC) and the 2021 case series on semaglutide injection-site nodules (PMC).

FDA consumer warnings including the FDA alert on dosing errors with compounded injectable semaglutide and the FDA's "Safely Using Sharps" guidance.

The 12-week rotation map is our editorial construction. Manufacturer labels require rotation, but no label specifies a 12-week schedule. FITTER supports systematic rotation and 1 cm spacing between consecutive injections, but does not prescribe this exact pattern.

We re-verify when...

An FDA-approved GLP-1 updates its injection-site language
A new injectable GLP-1 receives FDA approval
FITTER, the ADA, or another major body publishes updated injection-technique guidance
The FDA issues a new consumer warning related to GLP-1 administration
A product on the matrix is discontinued or returns to market

What we did NOT verify

International labels for these medications
Specific protocols at individual compounding pharmacies
State-by-state sharps disposal regulations (we link to the FDA's lookup tool instead)
Whether the information is appropriate for any individual patient — that is a conversation between you and your prescriber

When to Call Your Prescriber

Most rotation questions don't need a clinician. These do:

Confusion about your specific device

New pen type, switching from pen to vial, first compounded prescription, or the instructions don't match what you have in your hand.

Repeated injection-site reactions

Recurrent bruises, persistent lumps, expanding redness, areas that don't recover after weeks.

Combination injection therapy

You also use insulin or another injectable medication and need a coordinated rotation plan.

Accessibility limitations

Vision impairment, dexterity issues, difficulty reaching the abdomen or thigh, no available helper for the upper arm.

Symptoms beyond the injection site

Severe abdominal pain, persistent vomiting, signs of dehydration, or any symptom you weren't expecting from your medication.

Signs of a serious allergic reaction (hives spreading across your body, swelling of the face or tongue, difficulty breathing): call 911 or get to an emergency room. Don't wait to call your prescriber first.

The One Thing to Remember

Same area is okay.
Same exact spot is the problem.
Always inspect.

Stay 2 inches from your belly button. Stay a finger-width from your last injection. Pick a system you can actually follow. Use the 12-week map above if you don't already have one. Inspect your skin before every dose. And when in doubt, call your prescriber instead of asking the internet.

Related pages on this site

Not sure which GLP-1 program gives you the best device support and clinician access?

Get your personalized match based on your situation, state, and budget.

Take the free 60-second matching quiz Want FDA-approved? See Ro →

This page is an educational resource compiled by our editorial team from FDA-approved prescribing information, peer-reviewed pharmacokinetic studies, and the 2025 FITTER Forward expert recommendations. It does not replace the Instructions for Use that came with your medication, and it does not constitute medical advice for any individual patient. Use this guide alongside, not instead of, the guidance from your prescribing clinician. Last verified: May 9, 2026.